Project/Area Number |
22501056
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Clinical oncology
|
Research Institution | Japanese Foundation For Cancer Research |
Principal Investigator |
TAKAHASHI Syunji 公益財団法人がん研究会, がん化学療法センター臨床部, 研究員 (90221358)
|
Co-Investigator(Kenkyū-buntansha) |
ITO Yoshinori 公益財団法人がん研究会, がん化学療法センター臨床部, 研究員 (00261131)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 乳癌 / 骨転移 / 骨髄微小転移 / 骨微小環境 / ビスホスホネート |
Research Abstract |
To elucidate the interaction of disseminated tumor cells in bone marrow (DTC) and bone microenvironment and the effects of bisphosphonates in early breast cancer, we treated breast cancer patients with neoadjuvant chemotherapy with zoledronic acid (ZA), and examined pathological response and changes of DTC, circulating tumor cells (CTC) and circulating endothelial cells (CEC). We treated 30 patients and had Grade 2 to 3 response in 9 patients. CTC was positive in three patients and all became negative after chemotherapy. CEC increased with chemotherapy. Chemotherapy with ZA may increase CEC, and CEC may become a biomarker of neoadjuvant chemotherapy. DTC was positive in only three patients and tumor cells were few, so it was difficult to investigate interaction between tumor cells and cells in bone micro-environment. It should be necessary to investigate interaction between tumor cells and cells in bone micro-environment in the samples of bone metastases
|